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Abstract. Two mouse urokinase-type plasminogen
activator receptor (muPAR) cDNAs were isolated:
muPAR1 is homologous to the human urokinase-type
plasminogen activator receptor while muPAR2 codes
for a 199 residue protein sharing the first 133 residues
with muPARl. Mouse genomic DNA sequencing indi-
cates that the two different mRNAs arise by alternative
splicing. In situ hybridization showed differential ex-
pression of the two mRNAs in mouse gastric mucosa .
muPARI mRNA is located in luminal epithelial cells
situated close to urokinase-type plasminogen activa-
LASMIN-mediated extracellular proteolysis generated
by the urokinase-type plasminogen activator (uPA)'
is involved in a variety of normal and pathological
processes that require cell migration or tissue destruction,
such as involution of the mammary (Ossowski et al., 1979;
Larsson et al., 1984)and prostate (Andreasen et al., 1990b)
glands, trophoblast invasion (Strickland et al., 1976; Sap-
pino et al., 1989), spermatogenesis (Vihko et al., 1988),
wound healing (Grondahl-Hansen et al., 1988), and cancer
invasion (Reich, 1978 ; Ossowski and Reich, 1983; Skriver
et al., 1984; Dano et al ., 1985 ; Bergman et al., 1986; Mig-
natti et al., 1986; Saksela and Rifkin, 1988 ; Grondahl-
Hansen et al ., 1991). The regulation of the uPA pathway of
plasminogen activation is quite complex. uPA is released as
a virtually inactive single chain pro-enzyme, which by
limited proteolysis is converted to two-chain active uPA. The
uPA activity is regulated both temporally and spatially in
time and spaceby two specific plasminogen activator inhibi-
tors, PAI-1 and PAI-2 (Seifert and Gelehrter, 1978 ; Schleef
and Loskutoff, 1988; Andreasen et al., 1990x), and by a
specific cell surface receptor for uPA (Vassalli et al., 1985 ;
Stoppelli et al., 1985).
The human uPA receptor (huPAR) has been purified and
characterized, and a complete cDNA has been isolated. It is
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tor-producing connective tissue cells of the lamina
propria, pointing to plasmin generation controlled by
the cooperation of different cells that may play a role
in the release of gastric epithelial cells. muPAR2
mRNA is expressed in the basal epithelial cells, and
the deduced protein sequence includes the receptor
ligand binding domain, but omits the region involved
in glycolipid-mediated membrane anchoring, suggest-
ing that muPAR2 may code for a secreted uPA binding
protein .
a cysteine-rich, highly glycosylated 55-60,000 M protein,
synthesized as a 313 amino acid residue peptide preceded by
a signal peptide (Nielsen et al., 1988 ; Estreicher et al.,
1989; Behrendt et al., 1990; Roldan et al., 1990), which is
anchored to the cell surface by a phosphatidylinositol glyco-
lipid anchor (Ploug et al., 1991b). The mature huPAR con-
sists of three repeats which appear to represent different
domains, the NH2-termina187 residues constituting the uPA
binding domain (Behrendt et al., 1991) . The humanreceptor
is present on the surface of a variety of cultured cell lines of
neoplastic and non-neoplastic origin (Blasi et al., 1987;
Blasi, 1988; Nielsen et al., 1988). huPAR mRNA has been
identified in colon cancer cells in situ at invasive foci, ad-
jacent to uPA producing stromal cells (Grondahl-Hansen et
al., 1991; Pyke et al., 1991). huPAR binds humanuPA with
a high affinity that varies between cell types. Concomitant
binding ofpro-uPA to uPAR and of plasminogen to as yet un-
identifiedbinding sitesstrongly enhances plasmin generation
on cell surfaces (Plow et al., 1986; Ellis et al., 1989, 1990;
Stephens et al., 1989). In some cell types, receptor-bound
pro-uPA is localized on cell-cell and focal cell-substratum
contact sites (P6llanen et al., 1988 ; Herbert and Baker,
1988) .
We have previously studied murine uPA (Dan¢ and Reich,
1978; Dano et al., 1980; Skriver et al., 1982) and the occur-
rence of this protein and its mRNA in situ under both normal
(Larsson et al., 1984; Vihko et al., 1988; Andreasen et al.,
1990b; Kristensen et al., 1991) and pathological conditions,
including wound healing (Grondahl-Hansen et al., 1988)
and cancer invasion (Skriver et al., 1984; Kristensenet al.,
1990). No structural information has been reported about
the mouse uPA receptor (muPAR), in contrast to the increas-ing amount of information available concerning huPAR.
Characterization ofmuPARis an importantbasisforperform-
ing functional studies of the plasminogen activation system
in the mouse and to achieve this goal we have now isolated
cDNA encoding the mouse receptor and surprisingly found
two different types of muPAR mRNA, which are produced
by alternative splicing and are differentially expressed in the
mouse gastrointestinal tractas shownby in situ hybridization.
Materials and Methods
cDNA Cloning
Two fragments of the huPAR cDNA (Roldan et al., 1990) were used for
screening: Pstl fragment (268 bp) (bp 185-453) and BamHI fragment (585
bp) (bp 498-1083). DNA fragments were labeled with 32P-dCTP by using
a random priming kit (Boehringer Mannheim Biochemicals, Indianapolis,
IN), and hybridization conditions were determined by Southern hybridiza-
tionto human and mouse genomic DNA. 1.5 x 106 plaques from a mouse
macrophage lambda gtll library (Clontech, Palo Alto, CA) were screened
on duplicate Genescreen filters (NEN Dupont, Boston, MA) at 42°C in
35% formamide, washed at increasing stringency until 47°C in 0.1 x SSC
with 1% SDS, and 62plaqueshybridizingwith theBamff fragmenton both
duplicates were identified. After removal ofbound probe by boiling, filters
were rescreened with the Pstl fragment under the same conditions and 82
positive plaques were found. A comparison showed that 22plaques hybrid-
ized with both the BamHI and Pstl fragment. Four lambda clones were
purified by three rounds ofplaque purification, and inserts were subcloned
into a plasmid vector (pBluescriptKS(+))(Stratagene, La Jolla, CA) and
analyzed by restriction mapping and dideoxynucleotide DNA sequencing
with Sequenase (UBS, Cleveland, OH) with a combination ofnested Exo-
nuclease III deletions and synthetic oligonucleotide primers. Sequence ho-
mology searching was performed using the FastA/TFastA methods (Pear-
son and Lipman, 1988) as implemented in the GCG package (Devereux et
al., 1984), using word sizes of six and one, respectively.
In Vitro Translation
Plasmid DNA containing the muPARI or muPAR2 cDNA was linearized
with SspI, and sense RNA was prepared in transcription reactions contain-
ing: 2 .5 ug DNA template, 40 mM Tris-HCI, pH 7.6, 6 mM MgC12, 10
mM NaCl, 2 mM spermidine, 10 mM DTT, 0.5 mMofeach ribonucleotide,
and 60 U ofthe appropriate polymerase (T3/T7) (Promega Biotech, Madi-
son, WI). After incubation for 120 min at 37°C, 5 U of RQIYDNase
(Promega Biotech) was added and incubation continued at37°C for 15 min.
After phenol/chloroform extraction, theRNA was precipitated with ethanol
and redissolved in diethylpyrocarbonate-treated water. One fifth of the
generated RNA was used for in vitro translation using 35S-labeled cystein
(Promega Biotech). 1150 ofthe translation reaction was analyzed by SDS-
PAGE and fluorography.
PCR Amplifications
1 ag ofmouse genomic DNA (Balb/c) (Clontech) was added to a reaction
containing 25 pmol primer 1:S-GAGCTGTGAGAGGGGCCGG, 25 pmol
primer 2: 5'-CCACAGCCTCGGGTGTAGTCCT, 1 mM of each deoxy-
nucleotide, 10 mM Tris-HCI, 50 mM KCI, 1.5 MM M9Cl2 and 1 U Perfect
Match (Stratagene). After initial denaturation for 5 min at 94°C, 2.5 U of
AmpliTaq polymerase (Perkin Elmer Cetus, Norwalk, CT) was added and
amplification for 40 cycles of 94°C (30 s), 55°C (30 s), and 72°C (2 min)
was performed. 2 U of Klenow polymerase (Boehringer Mannheim Bio-
chemicals) was added to 1110 of the PCR reaction and incubated for 15 min
at 37°C. After agarose gel electrophoresis, the DNA was purified using
Geneclean (Biol01, La Jolla, CA) and cloned into the SmaI site of pBlue-
scriptKS(+). The DNA sequencewas determinedusingthe dideoxy method
and synthetic oligonucleotides.
RNA was isolated frommouse stomach mucosa (fundus or antrumpart)
according to the method ofChomczynski and Sacchi (1987). 5 ug of RNA
was used for first strand cDNA synthesis in a reaction containing 25 pmol
primer 2, 2.5 mM ofeach deoxynucleotide, 10 mM Tris-HCI, 50MM KCI,
1.5 mM MgCl2, 10 U of RNasin (Promega Biotec), and 60 U ofAMV re-
verse transcriptase (Promega Biotec). The reaction was incubated at 23°C
(10 min), 42°C (60 min), and 94°C (5 min). The reaction was then diluted
fivefold maintaining Tris, KCI, and M9Cl2 concentrations and after addi-
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tion of primer 1 (25 pmol) and 2.5 U of Amph"aq polymerase amplified
for40 cycles at 94°C (1 min), 55°C (1 min), and 72°C (2 min). The ^330
nucleotide DNA fragment waspurified fromtheagarose gel and reamplified
using the same conditions. 5 pl of this second reaction was used for asym-
metrical amplification using 100 pmol of one primer and 0.5 pmol of the
other, or reverse. The products ofthe asymmetrical reaction were purified
by Geneclean and each sequenced using the dideoxynucleotide method
using the primerpresent in low amount in thepreceding asymmetrical am-
plification.
In Situ Hybridization
RNA probes were generated from three subclones of the cDNA in
pBluescriptKS(+). The NH2-terminal XboI fragment was subcloned
generating a plasmid containing bases 1-366. By PCR amplification with
primer 1 and 2 (as described above) a second fragment including bases
512-698 of muPAR2 was isolated and subcloned into the Smal site of
pBluescriptKS(+). The COOH-terminal probe common to both muPAR1
and muPAR2 was generated by PCR amplification between nucleotide
701-1186 of muPARI, using 18-mer oligonucleotides with added synthetic
BamHIor HindIII sites and subcloned intopBluescriptKS(+) digested with
these enzymes. The DNA sequence and orientation of the inserts in the
three clones wereconfirmed by DNA sequencing. RNAprobes for detection
of uPA mRNA was generated from the plasmid pMUPA07 (Kristensen et
al., 1991). 35S labeled antisense and sense RNA was prepared from linear-
ized templates and used for in situ hybridization ofcryostat sections as de-
scribed (Kristensen et al., 1991).
Results
Isolation and Characterization ofmuPAR cDNA
Two non-overlapping fragments from the coding region of
humanuPA receptor cDNA were used sequentially to screen
a mouse macrophage lambda gtll cDNA library under non-
stringent conditions. 22 plaques hybridized with both frag-
ments and 4 were plaque purified. DNA sequencing and
restriction enzyme analysis demonstrated that one clone
(designated muPARI) resembles the known huPAR cDNA,
whilethe other three (muPAR2) were similar to muPARI ex-
cept for two regions: an insertion of 218 by at nucleotide
number 480 and startofthe polyadenylated region at an ear-
lierpoint than muPAR1(Fig. 1). Two ofthe muPAR2 cDNAs
were completely identical, whileone had an additional aden-
osine in the polyA(+) tail.
The muPARI cDNA sequence is homologous to that of
huPAR (Roldan etal., 1990), diverging however significantly
in the 3' untranslated region (Fig. 1). The muPAR1 cDNA
is probably incomplete as it contains 453 nucleotides after
the translation termination codon TGA, but no poly-A tract.
It codes for a 304 amino acid protein, with a putative signal
peptide of 22 residues. In comparison with huPAR, muPARI
has two additional amino acids at positions 83 and 258, but
lacks three amino acids following residue 134, seven amino
acids following residue 273, and one after residue 299. As
shown in Fig. 1, all cysteine residues are conserved; overall
muPARI and huPARhave 62 % amino acid identity and 70%
homology when conservative substitutions are included. The
COOH-terminal sequence of the muPARI protein is slightly
more hydrophobic than huPAR but probably still insufficient
for transmembrane attachment of this receptor. It is thus
likely that muPAR1 is attached to the membrane by the phos-
phatidyl inositol mechanism as demonstrated for huPAR
(Ploug et al., 1991b).
In the muPAR2 cDNA 218 nucleotides are inserted at po-
sition 480. Following this insertion the DNA sequence again
becomes identical to that of muPARI, and the identity con-
1764muPARI GAGAGTAACCAGAGCTGCCTGGTAGAGGAGTGTGCTCTGGGCCAGGACCTCTGCAGGACTACCGTGCTTCGGGAATGGCAAGATGATAGAGAGCTG
￿
194
muPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
huPAR A"'CC'"GGGGAT""GT"G"A""'C"C""'A""""""""'C"GA'CG'G'CTTG"'G""A'GAGA"""226
muPARl G1uSerAsnGinSer y
￿
uValG1UG1 y laLeuGlyGl.ASpLe y rgTh~hrValLeuArgGluTrpGlnASPASpArgGluLeu
￿
38
muPAR2
￿
38
hUPAR LySThr ' GlyASp4rg '
￿
Ileval ' Lau ' GlUGlUGlyGlu '
￿
38
muPARl GAGGTGGTGACAAGAGGCTGTGCCCACAGCGAAAAGACCAACAGGACCATGAGTTACCGCATGGGCTCCATGATCATCAGCCTGACAGAGACCGTG
￿
290
muPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
huPAR "'C""'GAGAA' . . . .A . . . . .TCA"G""' . . . . . . . . . .C . . . .C"T . .G'CT" . .TG.A . . . . .C . . . . . .T. .C . . .GTT . . . 322
muPAR1
muPAR2
huPAR ' Leu GluLysSerL~_Fhr
￿
' Leu
￿
Thr LeULys ' Thr '
￿
' Val '
muPAR1 TGCGCCACAAACCTCTGCAACAGGCCCAGACCCGGAGCCCGAGGCCGTGCTTTCCCTCAGGGCCGTTACCTCGAGTGTGCGTCCTGCACCTCTTTG
muPAR2 - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
huPAR
￿
- T'GGTT'G
￿
T'G" "
￿
CA'GGC'ACT T" C---"G'CTGTCA'C'ATT-C'GAA
￿
.. . . .A'' CATT . . . . .TGG" A'CA
hrSerLeu muPAR1
mUPAR2
hUPAR
Fy
mupAR1 -
muPAR2 PhsEnd
huPAR -
GluValValThrAr9Gly laHisSerGluLysThrAsnArgThrMetSerTyrArgMetGlySerMetIleIleSerLeuThrGluThrVa1
laThrAsnLeurysllsnArgProArgProGlyAlaArgGlyArgAlaPheProGlnGlyArgTyrLeuGlt~
PlyLeuAsp ' L- ~' GlnGlyAsnSer ' - ' AlaValThrTyrSerArgSer '
￿
'
huPAR ' Met
￿
His '
SarLeULysAspGluAspTyrThrArgGl
ArgPro
￿
. AspArgHisLeu '
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y
l
GlIrSex y LLJLss GlyASSerThrHss Gl~er8erGluGlvTh=p
he
LeuIleA As s~rgGlyProMetASnG1
hUPAR Arg
muPARI GACCAGAGCTGTGAGAGGGGCCGGGAGCAAAGCCfGCAATGCCGCTATCCTACAGAGCACTGTATTGAAGTGGTGACCCPCCAGAGCACAGAAA--
￿
480
482
511
muPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . GT
huPAR
￿
"'AT . . . . . . . . . . . . . . . . . . . C'C"G""""G'
￿
AGC"'GA- A"G. . CC . G 'T"""""A'TG' T'CAG"'GGT
muPARI AspGlnSer"luArgGlyArgGluGlnSerLeuGlnrys~rgTyrPrOTh~luHi y IleGluValValThrLeuGlnSerThrGluArg
￿
134
Ser 134
' Ser ' Glu ' Gl
￿
UASP
￿
HisTrPIleGln ' Gly
￿
133
.UPARI -------------------------------------..----------------------------------------------------------
muPAR2 AAGCTCCCATCTGCTGGGCAACTCCTAGTAGAGATCTTCAAGTCCTGGGAGCAGAGCGCAAGCAAGAGACAACTGAATCCACACACAGTCACAGGA
￿
578
huPAR GAAGAAG-----------------------------------------------------------------------------------------
muPAR2 LyaLeuProSerAlaGlyGlnLQULeUValGlUIlePheLySSerTrPGIUGlnSerAlaSerLysArgGlnLeuAsnProHisThrValThrGly
￿
166
MUPARI ------------------------------------------------------------------------------------------------
muPAR2 CCAACATTCTCAGTGACTGGAAGTTCCGGGTCACTGGATCAGCTTGGGAGTGACCAGGAACCCAGCIACCTTGTCATGTCICGCATATTGCTTTCG
￿
674
hUPAR ------------------------------------------------------------------------------------------------
muPAR2 ProThrPheSerValThrGlySergerGlySerLeuAspGlnLeUGlySerAapGlnGluProSerTyrLeuValMetSerArgIleLeuLeuSer
￿
198
muPARl ------------------------GGAGCTTGAAGGATGAGGACPACACCCGAGGCTGTGGCAGTCTTCCCGGATGCCCAGGCACAGCAGGTTTC
muPAR2 TTCTGATGACTGCCTCATGGCACA" . . . . . . . " .' .
. .
. .
.
. .
.
. ' .' . . . . .
. .
' .
.
.
. .
.'
.
. .
.
.
.
. .
.
.
. " ' . . . . . . . . . . . . . . . .
551
769
hUPAR
￿
------------------------" C' TCCA" " '
￿
. ' CCG' C" CT" ' T. . . . . . . . . TAC. . . . . . . .C . " 'G. . ' T' CAAT . . . . . .
￿
589
lySerLeuProGlypysl?roGlyThrAlaGlyPhe
muPAR1 CATAGCAACCAGACf.T1TCACPTCCTGAAGTGTTGCAACTACA000ACTGCAATGGTGGCCCAGTTCTGGATCTTCAGAGCTTTCCACCGAATGGC
￿
647
muPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
￿
865
huPAR
￿
"C A""G'C . . . . .C. . . . . . . . . . . A''C'
￿
"'AC""A'A. . . . .CAG"""A'C""'G"'G'A'ATC'G"G'A685
muPARl HisSerAsnGlnThrPhoHi .Ph.LeuLy Cy
￿
snTyrThrHis
￿
snGlyGlyProValLeuhspLeuGlnSerPheProProAsnGly
￿
189
huPAR
￿
' Asn ' Asp '
￿
' Thr ' Lys~' Glu ' ' Ile ' Glu ' GluAsnLeu Gin '
￿
191
muPAR1 TTCCAGTGTTACAGCTGTGAGGGGAACAATACCCfTGGGTGTTCCTCCGAAGAGGCGTCTCTCATCAACTGCCGGGGACCAATGAATCAGTGCCTG
.UPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
huPAR
￿
CG . . . . . . . . . . . . . . .CA. . . . . . . . .GC. . . .A . . .A . .C . . . . .T . . . . . .A .T .TC. . . . .TG. . . . . . .A . .C . .C- .
. . . . .
A. .T .
.UPARI GTGGCTACAGGCTTAGATGTGCTGGGAAACCGGAGTTATACCGTAAGAGGCTGCGCCACGGCTTCCTGGTGCCAAGGCTCCCACGTGGCAGACTCC
muPAR2 * . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
839
1057
huPAR
￿
--A" C" C"
￿
ACTC' C' AA' C AA" "' AA" C. . . . TG . . . . . .
￿
-
￿
I A . .C" C"AAT. . . . . . . CATG" '
￿
C" -GT --G--
￿
877
muPARI ValAlaThrGlyLeuAspValLeuGlyAsnArgSerTyrThrValArgGly y laThrAlaSerT
￿
GlnGlySerHisValAlaAspser
￿
253
huPAR
￿
ThrHisGluPtoLyB ' Gin ' ' Met '
￿
' Nee' ' HisAla ' LeuGly ' Ala
￿
255
mUPARl TTCCCGACCCACCTCAACGTCTCTGTCTCCTGCTGCCACGGCAGCGGCTGTAACAGCCCC---------------------ACAGGGGGCGCCCCC
￿
914
.UPAR2 ' . . . ". ." ' .' ."
￿
''' .' . .' . . . . . . . . . ' . . . . .
.
. . . . . . . . . . . . . . . . . . . ------------------------- . . . . . . . . . .
￿
1132
huPAR
￿
" 'AGC'TGA" ---C"A'TGA . . . . . . . .
￿
. TACTAAA" T"
￿
'CA" 'AGACCTGGATGTCCAGTACCGC'GT"
￿
- CT -- T- . T
￿
970
muPARI PheProThrHiSLeaAnValSerValSe y y isGlySerGlyFsksnSerPro - - - - - - - ThrGlyGlyAlaPro
￿
278
huPAR
￿
' SerMetAsn - HisIleAsp '
￿
hrLys .
￿
His
￿
AspLeuASpValGlnTyrArgSer
￿
Ala
￿
286
mupARI AGGCCAGGCCCTGCTCAACTCAGCCTCATTGCCTCTCTGCTCCTGACCCTCGGACTATGGGGC---GTCCTCCICTGGACCPGACPCCTGAGCCGG
mu1AR2 - . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1007
1225
huPAR
￿
CA'
￿
T'
￿
C 'I**''
￿
" " ' CCAT' A' C'
￿
. ' . AA" " TGC A"
￿
-G-
￿
"
￿
AGGCACT"
￿
" "" " TAAAC' TGA AT' CC
￿
1066
muPARI ArgproGlyProAlaGlnLeUSerLeulleAlaSerLeuLeuLeuThrLeuGlyLeuTrpGly - Va1LeuLeuTrpThrEnd
￿
304
hUPAR Gin '
￿
His
￿
ThrIleThr '
￿
Met AlaArg
￿
GlyThr '
￿
End
￿
313
.UPAR1 CAGCCCTGGCTGGACCCAGGGTCTTTTGACTCCCTCCCCCCTGCTCCATCTTTGAGGATGTGTGTGCCCTCGTGTTGTCTTCTTTGGACCTCAGTT
muPAR2 -- . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1103
1321
huPAR
￿
CCT T'
￿
C CT'G'TGGATCCGGGGGAC'C'TT'G" 'TTCC" 'GGCTCCCAGCCC'ACAGACTTG" GTGTGACCTCAGGCCAGTGTGCCGAC
￿
1162
muPARI TTTCCATGAACCAGAAGAGAATTGGAACAAGGGCTGCGGGCAGCAGGGGCCTCTTAGTTGAGATAATATTGTTGCTGTTATTATTATTATTATCAT
muPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
70
70
70
386
386
415
102
102
101
157
199
159
743
961
781
221
223
1199
1417
huPAR
￿
CTCT'TG'GC'TCAGTTTTCCCA'CP'TG'AAA'A" TATCTCACAAA TTGTG GAAGC"'AG'G'AAAGCTGGAGG'AGGCCGTGGGCAATGG
￿
1258
muPARI TGTTATTGCTCTAATTTATTATATAAATATATATATAAAAGATITTTGTACCAGTGAATAAGGTTGGGTCTCCCCACTGTCACATTTAGCTTGGGA
￿
1295
muPAR2 ' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .AAAAAAAAAAAAAA'A
￿
1474
huPAR
￿
GAGAGC - CT G' T'
￿
AT' A' ' ' 'TGT' GCCGC' G' TGTGTTG' 'G' TATTA' T' A' TATTCA'ATTA' T' ATTTTA' ACTTACA A AGA' TTTG
￿
1354
MUPARl AGATGAGAGCAGCAGGGAATTGTTITiTTGTTTGTTTGTTTGTTTGTTTGATTGATTGATTTTTGCTTTGAGACAGGATCTCACCATGTAGCCCIA
￿
1391
huPAR TACCAGTG A'AA'AAA'' 1406
muPAR1 GCTGCCCCGCCGATACTGACGGGCTCCAGGAGTCGTCGCCACCGGGCTGCAGGAAT
￿
1448
Figure 1. Sequence of thetwo
muPAR cDNAs isolated and
theaminoacid sequence ofthe
corresponding proteins as pre-
dictedfromthecDNAsequence
data. Thedata arealigned with
theuPAR DNAandproteinse-
quences (Roldanet al., 1990).
The NH2-terminal of the ma-
ture protein is underlined, po-
tential N-linked glycosylation
sitesofmuPARl are indicated
by asterisks (*), and the con-
served cysteine residues are
boxed. Thesequence data are
available from EMBL/Gen-
Bank/DDJB under accession
numbers 62700 (muPARI)
and 62701 (muPAR2).
.UPARl CGGAAGAACCCATGGGACTCCCAAGGCGGCTGCTGCPGCIGCIGTTGCTGGCGACTACCTGTGTCCCAGCCTCCCAGGGCCTGCAGTGCATGCAGTGT 98
mUPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
98
huPAR GCCCICGCGAC. . . . . T.A. . .GCC" T. . . . .C' . . . . . . . . .C . . . .CCAC--- . . . . .C . . . . . . . . . . .TTG . . . . . . . .G . . . . . . . . . . . . . 130
muPAR1 MetGlyLeuProArgArgLeuLeuLeuLeuLeuLeuLeuAlaThrThr~alProAlaSerGlnGlyjgyGln~.fetGln 6
mUPAR2 6
huPAR ' ' His ' ProLeu ' Pro ' ' His - . .. . Trp ' ' Argu ' ' 6tinues until nucleotide 1240 of muPARI . At this point, a
short (14 nucleotide) stretch ofAs is present, which makes
a 20 nucleotide long poly A-tail, terminating the muPAR2
cDNA . The insertion contains two stop codons in tandem
(nucleotide 678-683) and themuPAR2 cDNA therefore only
codes for a total of 199 amino acids . The protein shares the
first 133 amino acid residues with muPAR1, followed by 66
additional residues which are unique for muPAR2 (Fig . 1) .
The 66 amino acid stretch encoded by this insertion is not
particularly hydrophobic . The absence ofcysteines from this
sequence is noteworthy, as this leaves an uneven number of
cysteine residues in the protein . The insertedDNA and pro-
tein sequences do not shown significant homology toknown
nucleic acid or protein sequences in the GenBank/EMBL
database.
In 11tro Translation
The insertion of 218 by found in the muPAR2 cDNA leads
to the premature termination of the receptor protein. Com-
plete cDNA sequence of this insert region was determined
on both strands in all three cDNA clones and found to be
identical ; the presence of the stop codons was further
verified by in vitro translation of synthetic mRNA prepared
from the muPAR1 and muPAR2 cDNA . Indeed, it was
demonstrated that whilemuPARI codes for translation prod-
Figure 2. SDS-PAGE of in vi-
tro translationproducts gener-
ated using rabbit reticulocyte
lysate, 35S-Cystein, and syn-
thetic RNA generated from
the two mouse uPA receptor
cDNAs . (Lane 1) muPARl
mRNA; (lane 2) muPAR2
mRNA. Size of molecular
weight markers is indicated.
protein
muPAR1
mRNA
muPAR gene
muPAR2
mRNA
protein
1 2
TheNo Forms ofmuPAR mRNA Arise by
Alternative Splicing
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Figure 4 . Schematic representation of the relationship between the
partial genomic clone, the isolated muPAR1 andmuPAR2 cDNAs,
and thepredicted twodifferent uPAR binding proteins . (1) Predicted
signal sequence. (2) Domain homologous to the region of huPAR
responsible for uPA binding. (3) Region homologous to the part of
huPAR removed during posttranslational attachment of glycolipid
anchor. The hatched bar represents the DNA/protein sequence
unique to muPAR2 and the whitebar in themuPAR gene represents
the intron sequence spliced out in both muPAR1 and muPAR2 .
ucts with a predominant molecular weight of ti 35,000, the
muPAR2 cDNA only codes for a protein with a molecular
weight of ti 24,000 (Fig. 2), confirming that the insertion in
muPAR2 leads to an earlier termination of protein transla-
tion . No microsomes were added to the translation reaction
so, presumably, the doublet observed withmuPARI RNA is
the result of incomplete translation .
ADNA clone containingmouse genomicDNA was isolated
byPCR amplification with two primers located on either side
of the point of insertion in muPAR2 (see Materials and
Methods) . The isolated DNA fragment was blunt-ended
with Klenow fragment, subcloned into pBluescriptKS(+),
and sequenced (Fig . 3) . Three base pair changes were found
in the genomic clone. These substitutions would change
Gly(177) to Arg(177) and Arg(194) to Pro(194) . However,
since the sequence ofthemuPAR2 cDNA specific region was
determined in three cDNA clones where at least two are in-
dependent clones, it is most likely that these differences are
caused by errors of the Tag polymerase early in the am-
plification procedure . The DNA sequence (Fig . 3) shows that
,-, 100 bp
AAAAAAAAAAAAA
Figure 3. DNA sequence of a
partial mouse genomic DNA
clone isolated by PCR ampli-
fication. Base pairs differing
in the gene from muPAR2 se-
quence are shown . The splic-
ing point responsible for the
difference between muPAR1
and muPAR2 is indicated by
an asterisk (*) and the sequence
not found in muPAR1 and
muPAR2 is indicatedby dashes.
The sequence found in the 3'
end of the utilized primers is
underlined . This sequence is
available from EMBL/Gen-
Bank/DDBJ under accession
number 62702 .
gene TGAGAGGGGCCGGGAGCAAAGCCTGCAATGCCGCTATCCTACAGAGCACTGTATTGAAGTGGTGACCCTCCAGAGCACAGAAAGTAAGCT 90
muPAR2 487
gene CCCATCTGCTGGGCAACTCCTAGTAGAGATCTTCAAGTCCTGGGAGCAGAGCGCAAGCAAGAGACAACTGAATCCACACACAGTCACGGG 180
muPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A . . 577
gene ACCAACATTCTCAGTGACTGGAAGTTCCCGGTCACTGGATCAGCTTGGGAGTGACCAGGAACCCAGCTACCTTGTCATGTCTCCCATATT 270
muPAR2 . . . . . . . . . . . . . . . . . . . . . . . . . . . .G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .G . . . . . . 667
gene GCTTTCGTTCTGATGACTGCCTCATGGCACAGTATGGCCACCATAATTCCAGACTTGGTGTCCACATTCCAGAGAGAAGAAAAGGGGAAA 360
.UPAR2 698
gene GAAGGGCCCCAAAATTCCITIGTTTTGTAAGGGTTTTCTTTCTAGAAATCCCAGAAACGCATAAGGATCTATTTATCGTTCGGGCCTCCT 450
muPAR2 ------------------------------------------------------------------------------------------
gene TTATCTATAACAAAGGGGAAAAGGAACTCGAAGCCCTTTGGCTAAGGATGAAGTTACCCTAAGTAGCAAGGGCCTCTGATAAAAGGGGTG 540
MUPAR2 ------------------------------------------------------------------------------------------
gene TGCGCAAGGGGGCAAATCAACACCCAGCCCCTTACCAGGATCTGCCCTCTGCCTTCTGCAGGGAGCTTGAAGGATGAGGACTACACCCGA 630
muPAR2 ------------------------------------------------------------------------------------------ 727Figure S . In situ hybridization analysis of adjacent cryostat sections of mouse ventricular mucosa using 35S-labeled antisenseRNA from
anNH Z-terminal subclone common to both mouse uPA receptormRNAs (muPARI and muPAR2) (a and b), antisense RNA specific for
muPAR2 (c and d) or mouse uPA antisense RNA (e andf) . After hybridization sections were covered with emulsion and exposed for
7 d . Sections are viewed by either transmitted light (a, c, and e) or using dark-field illumination (b, d, andf) . Asterisks indicate gutlumen .
Bar, 100 um .
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1767Figure 6 . High power magnification of two adjacent sections from the luminal part ofthe mouse ventricular mucosa hybridized with 15S-
labeled antisense RNA from an NHZ-terminal subclone common to both mouse uPA receptor mRNAs (muPARI and muPAR2) (a) or
mouse uPA mRNA (b). Note that while signal for the uPA receptor mRNA is found over the entire luminal epithelium, the signal for
the corresponding ligand is found over distinct fibroblast-like cells just below in the lamina propria (arrows in b) . Asterisks indicate gut
lumen . Bars, 10 lm.
following the employed primerthe genomic clone starts with
70 nucleotides that are common to both muPARI and
muPAR2, continues with the 218 nucleotides unique to
muPAR2 followed by 300 nucleotides, and finally returns
again to sequence common to both muPARI and muPAR2
(now 3' untranslated region of the latter) . We therefore con-
clude that muPARI and muPAR2 arise from a common
precursormRNA by alternative splicing. The same intron in
fact can be spliced with two different donor sites generating
two different mRNA species. The overall relation between
themuPAR gene,muPAR1 andmuPAR2cDNA andmuPAR1
and muPAR2 proteins is summarized in Fig. 4 .
TheNo muPARmRNAFormsAre Differentially
Expressed in the Gastrointestinal Tract
By restriction enzyme digestion or PCR amplification three
subclones were prepared for generation ofRNA probes for
in situ hybridization (see Materials and Methods) . Antisense
RNA from two probes (designatedNHZ-terminal and000H-
terminal probe) will detect both muPARI and muPAR2
mRNA, while the third(designatedmuPAR2 probe) will rec-
ognize only muPAR2 mRNA, as it contains only the DNA
sequence unique for this clone . The authenticity of the gen-
erated constructions was confirmed by DNA sequencing of
the subclones . The corresponding antisense and sense "S-la-
beled RNA probes were generated and used to analyze the
distribution of the two types ofmRNA in the gastrointestinal
tract of themouse. In situ hybridization with AntisenseRNA
from the NHZ-terminal and COOH-terminal subclones
demonstrated signal over the epithelium ofboth the luminal
and basal parts of the gastric mucosa in the fundus (Fig. 5,
a and b), as well as in the antrum parts (not shown) . How-
ever, when the muPAR2-specific probe was employed, the
signal was only observed over the basal epithelial cells (Fig .
5, c and d) . The luminal epithelial cells, therefore, most
likely contain only the muPARI mRNA, while the basal epi-
thelial cells may contain either a mixture of muPARI and
TheJoumal of Cell Biology, Volume 115, 1991
muPAR2 or only muPAR2mRNA . Interestingly, mouseuPA
mRNA is found in distinct fibroblast-like cells situated lumi-
nally in the lamina propria (Fig . 5, e andf), where also the
mouse uPA protein previously was found (Larsson et al.,
1984) . Examination ofadjacent sections at a higher magni-
fication demonstrates that the epithelial cells that contain
signal for the NHZ-terminal receptor probe, are situated in
close proximity to the fibroblast-like cells containing the sig-
nal formouse uPA (Fig . 6) . Control experiments performed
by hybridization of adjacent sections with the same amount
ofthe corresponding sense RNA probes gave no signal (re-
sults not shown) . Hybridization to cryostat sections ofother
parts ofthe gastrointestinal tract (antrum, duodenum, andje-
junum) showed a similar pattern : the NHZ-terminal probe
giving signal over both luminal and basal parts ofthe epithe-
lium, while the muPAR2-specific probe only shows signal
over the basal parts of the epithelium (results not shown) .
To further demonstrate the presence of muPAR mRNA,
RNA was isolated from mouse gastric mucosa (antrum and
fundus) and used as template for first strand cDNA synthe-
sis . PCR amplification using primers flanking 391-515 by in
muPARI and 391-733 by in muPAR2 showed the presence
of two bands of ti 340 and 120 by as observed after agarose
gel electrophoresis (data not shown) . The ti340-bpband was
isolated from the agarose gel and used as template for asym-
metrical PCR amplification . Dideoxy nucleotide sequencing
of the resulting two single-stranded DNA preparations re-
vealed sequence identical to that ofthemuPAR2cDNA (219
bases downstream from basepairnumber 432 and 209 bases
upstream from basepair number 639 ofmuPAR2), demon-
strating the presence of the muPAR2 mRNA in the mouse
fundus RNA preparation .
Discussion
The existence of auPA receptor in the mouse has previously
been indicated by binding studies with mouse cell lines as
1768well as mouse spermatozoa (Huarte et al., 1987; Estreicher
et al., 1989) . The strong homology between muPAR1 and
huPAR allows us to conclude that the mouse (type 1) uPA
receptor has characteristics similar to the human. A promi-
nent feature ofthe huPAR is its carboxyl-terminal processing
and membrane anchoring by glycosyl-phosphatidyl-inositol
(GPI) (Ploug et al., 199lb) . Characteristic for GPI-anchored
proteins is the presence of a moderately hydrophobic region
of at least 17 amino acid residues close to the 000H-
terminal end ofthe nascent protein (Ferguson and Williams,
1988). In muPAR1 a hydrophobic region starts at residue 280
ofmuPAR1 and goes through to the COOH-terminal (residue
304) with no interrupting charged residues. However, it must
be notedthat seven residues are deleted from muPAR1 when
compared to huPAR (residues 275-281 in huPAR) immedi-
ately NH2-terminal to the region predicted to be the site of
GPI anchoring in huPAR (residues 282-284) (Ploug et al.,
1991b). Amino acids with small side chains (Gly, Asn, Cys,
Ser, or Asp) are preferred at the GPI attachment site as well
as at the adjacent two COON-terminal residues (Micanovic
et al., 1988; Berger et al., 1988). On this basis we propose
that the putative GPI-anchor in muPAR1 is attached at Gly
(275) or close to this residue.
The huPAR is a highly glycosylated protein, the deglyco-
sylated mature polypeptide chain comprising only x+35 kD
compared with the apparent molecular mass (55-60 kD) of
the mature glycoprotein (Behrendt et al., 1991). The five pu-
tative N-glycosylation sites in the human receptor (Roldan
et al., 1990) are all present with identical localization in
muPAR1, which in addition has two other potential N-glyco-
sylation sites (Fig. 1). In common with the human receptor
is also a very high cysteine content in muPAR1 (N9% in the
mature protein in both cases). This may reflect a high num-
ber of intra-chain disulphide bridges defining compact do-
main structures. Together with the high degree of glycosyla-
tion, this feature may render the receptors very resistant to
proteolysis, and thus well suited to function in a proteolytic
environment (Ploug et al., 1991x).
The huPAR consists of three repeats with low level internal
homology particularly in the number and location ofthe cys-
teine residues (Behrendt et al., 1991). These repeats are also
found in the muPAR1 protein and by analogy it is likely that
the uPA binding domain is also located in the NH2-terminal
repeat, i.e., within residues 1-87. The consensus sequence
of the three repeats in huPAR has the same cysteine spacing
pattern as three other GPI-anchored proteins (the Ly6a and
Ly6b lymphocyte activating antigens (LeClair et al., 1986;
Palfree et al., 1987; Palfree et al., 1988 ; Reiser et al., 1988)
and the squid glycoprotein Sgp-2 (Williams et al ., 1988). All
three repeats in muPAR1 share these homologies, strength-
ening the assumption that the homologies are of structural
significance and that they reflect the existence of a novel do-
main characteristic of a protein family, to which huPAR and
muPAR1 belong. The humanand mouse u-PA receptors are
quite species specific with respect to ligandbinding (Appella
et al., 1987; Huarte et al., 1988; Estreicher et al., 1989).
A number of differences are found in the 1-87 region, that
may account for this species specificity (Fig. 1).
The presence of muPAR1 mRNA in luminal epithelial
cellsat the neck of the glands in the gastric mucosa probably
reflects the presence of type 1 mouse uPA receptor. Mouse
uPA mRNA and protein is present in adjacent fibroblast-like
Kristensen et al. Alternative Splicing ofMouse uPA Receptor mRNA
connective tissue cells (Fig. 6) (Larsson et al., 1984; Kris-
tensen et al., 1991), and it is likely that uPA produced by
these cells is secreted and subsequently bound to the uPA
receptor on the epithelial cells; the receptor-bound uPA may
thenprovide proteolytic activity at the cell surface during the
continuous shedding of the latter cells, in keeping with our
previous proposal (Larsson et al., 1984; Kristensen et al.,
1991).
Recently, a similar cellular cooperation in the control of
plasmin generation has been found in human colon cancer,
where uPA is produced by one cell type (fibroblast-like cells
in the tumor stroma), whilethe uPA receptor is produced by
cancer cells at invasive foci (Grondahl-Hansen et al., 1991;
Pyke et al., 1991) . Likewise, a paracrine mechanism involv-
ing secretion of uPA from one cell type and subsequentbind-
ing to the receptor on another cell type has been proposed
for the uPA produced by epithelial cells in the vas deferens
ofthe mouse (Larsson et al., 1984; Huarte et al., 1987) and
bound by spermatozoa, presumably through the uPA recep-
tor. Together with the strong enhancement of cell surface
plasmin generation observed after receptor binding of pro-
uPA in vitro (Ellis et al ., 1989, 1990; Stephens et al., 1989),
and the fact that cell-surface bound plasmin is resistant to its
physiological inhibitor alpha-2-anti plasmin (Plow et al.,
1986; V. Ellis, personal communication), these findings sug-
gest thatthe binding ofuPA produced by one cell type to uPA
receptors on another cell type may play a role for physiologi-
cal generation of cell surface localized proteolytic activity.
Genondc DNA sequencing shows that muPAR1 and
muPAR2 mRNA arise by alternative splicing of pre-mRNA
transcribed from the same gene. Excision ofthe same intron
occurs at different positions in the two cases, the upstream
donor splicing point being different and the downstream ac-
ceptor point being identical, as also seen in other cases of
alternative splicing (Breitbart et al., 1987) .
The additional nucleotide sequence in the type 2 muPAR
mRNA contains two stop codons in tandem giving rise to a
protein containing the supposed binding domain for UPA, but
no hydrophobic region, thus, lacking a membrane-spanning
domain or a GPI-anchoring signal. muPAR2 may therefore
be a secreted, water-soluble, uPAbinding protein. Soluble
forms of membrane bound proteins have previously been
reported and in some cases it has been shown that they arise
by alternative splicing of pre-mRNA: examples are the neu-
ral adhesion molecule NCAM (Gower et al., 1988), the
growth hormone receptor (Baumbach et al., 1989), the EGF
receptor (Petch et al., 1990), and the transferrin receptor
(Shih et al., 1990).
The mRNA coding for muPAR2 is expressed in intact
mouse tissue: the basal epithelial cells in all analyzed parts
of the gastrointestinal tract show signal for muPAR2 as
demonstrated by in situ hybridization using an antisense
RNA probe specific for muPAR2. The corresponding sense-
RNA probe showed no signal when an equal amount ofprobe
was added to adjacent sections, giving only a background hy-
bridization pattern similar to that found with uPA sense and
antisense probes outside the fibroblast-like cells of the gas-
tric mucosa (Kristensen et al., 1991). Northern blot experi-
ments with RNA isolated from the gastric mucosa did not
give signal, presumably due to insufficient amounts ofRNA.
To substantiate the presence ofmuPAR2 mRNAin thistissue
we therefore used the RNA for cDNA synthesis and PCR
1769amplification. The DNA sequence of the largest resulting
fragment was determined and found to be identical to the
muPAR2 sequence. The primers employed were identical to
those used for isolation ofthe genomic clone, thus, spanning
the intron and assuring that we were not amplifyinggenomic
DNA. The results in this study clearly demonstrate that there
are two types of muPAR mRNA encoded by the same gene
and generated by alternative splicing. The protein sequences
predicted from the two mRNAs are different and both
mRNAs are expressed in the normal mouse with a different
distribution. That both mRNAs are translated in vivo ap-
pears likely, but remains to be demonstrated. The fact that
mouse uPA is not readily cross-linked to its receptor (Es-
treicher et al., 1989; H. Solberg and G. HOyer-Hansen, per-
sonal communication), as is the case for huPAhuPAR, com-
plicates the demonstration ofthe muPAR2 protein. However,
generation of muPARI and muPAR2 specific antibodies on
the basis of the data presented here, will hopefully clarify
this question .
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